US company plans sale campaign
Norcross, Georgia-based Guided Therapeutics, Inc. (OTCQB: GTHP), is planning a 2-week sales trip for its product LuViva® in India in September or October.
It has been approved to sell its rapid and painless testing platform based on its patented biophotonic technology, LuViva®. It is for testing women at cervical disease risk.
“Based upon mutual agreement of a Letter of Intent, we are planning a 2-week sales trip to the 6 major cities in September or October,” said the company expecting initial orders by the end of 2018.
The campaign is part of its commercial activities internationally, it said in a statement on 21 June 2018.
The company’s is seeking financing for further commercial growth.
Guided Therapeutics’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care.
In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. fiinews.com
